# Real-World Evidence on Clinical and Health Economic Outcomes among Pediatric Patients in Post-Acute Care Receiving Commercial Blenderized Tube Feeding Formulas

Henrikson, A.,<sup>1</sup> Desai, A.,<sup>2</sup> Allen, F.,<sup>1</sup> Li, O.,<sup>3</sup> Yeddula, S.,<sup>4</sup> Araujo Torres, K.<sup>1</sup>

<sup>1</sup>Medical Affairs, Nestlé Health Science, New Jersey, US <sup>2</sup>Market Access, Nestlé Health Science, New Jersey, US <sup>3</sup>Clarivate Data Analytics & Insights, Toronto, Canada <sup>4</sup>Clarivate Data Analytics & Insights, Bangalore, India

# BACKGROUND

- Enteral nutrition (EN) is an important, life-sustaining treatment for individuals with functional gastrointestinal (GI) tracts who are unable to consume adequate food orally.<sup>1-3</sup>
- EN may be an option for outpatients requiring a long-term alternative to oral nutrition, but who are otherwise able to live away from a hospital facility.<sup>4</sup>
- EN is often initiated in the hospital setting and may continue as part of post-acute care, as indicated and tolerated.<sup>4</sup>
- Healthcare professionals, patients, and caregivers are requesting tube feeding formulas including easily recognized ingredients and more real food.<sup>1,5</sup>
- Due to its clinical and economic benefits, the use of home enteral nutrition (HEN) as part of post-acute care is increasing in the US.<sup>6</sup>
- Intolerance of enteral formulas can be a challenge in children receiving HEN and can lead to increased healthcare resource utilization (HCRU).<sup>7</sup>

### OBJECTIVES

- To describe demographic and clinical characteristics of children receiving a commercial blenderized tube feeding (CBTF) formula in post-acute care.
- To evaluate clinical and health economic outcomes among these patients up to 168 days after hospital discharge.

# METHODS

- This was a retrospective observational study using nationally representative US claims data obtained from the Decision Resources Group Real World Evidence Data Repository; this database covers 98% of US health plans, including medical and pharmacy claims.<sup>8</sup>
- Inclusion criteria were age <14 years and prescription of CBTF (Compleat® Pediatric Organic Blends, Nestlé HealthCare Nutrition, US) as sole-source nutrition for at least 7 days in post-acute care.
- Patients treated for any reason between 1 January 2018 and 30 December 2020 were included.
- The index date was defined as the date of hospital discharge. Patient characteristics, concomitant medication use, GI intolerance symptoms, HCRU, and cost of care were recorded within one year before discharge and up to 168 days post-discharge.
- Outcomes were compared between the pre-index period (within 1 year before discharge) and post-index period (latest records at 28, 84, and 168 days post-discharge).
- Demographics, clinical characteristics, and concomitant medications were analyzed using statistics (median, mean, and standard deviations) and the appropriate univariate statistical test (chi-square, t-test, or non-parametric test) at the alpha=0.05 level of significance to compare pre-index and respective post-index outcomes at 28, 84, and 168 days post-discharge.


### RESULTS - PATIENT CHARACTERISTICS (TABLE 1)

- The study included 469 children using the CBTF formula in the post-acute setting (44% female; mean [standard deviation (SD)] age at index date 5.2 [3.32] years) from all regions of the US.
- Pre-index, the most common diagnoses were diseases of the digestive system (81%), respiratory diseases (78%), and congenital conditions (76%).
- The most common comorbidities were paraplegia and hemiplegia (28%), chronic pulmonary disease (28%), and cerebrovascular disease (7%).
- Among 277 patients (59%) with at least 1 additional comorbidity, 88% had a Charlson Comorbidity Index (CCI) score of 1 or 2 (mild comorbidity), 10% had a score of 3 or 4 (moderate), and 1% had a score of  $\geq 5$  (severe). The mean (SD) CCI score among patients with comorbidities was 1.6 (0.9).

#### Table 1: Patient characteristics (N=469)

Mean age, years (SD)†		
Gender, n (%)	Female	207 (44)
Charlson comorbidities occurring in at least 10% of patients, n (%)‡	Paraplegia and hemiplegia	132 (28)
	Chronic pulmonary disease	131 (28)
Mean CCI score (SD)†		1.6 (0.9)

Commercial blenderized enteral formulas are well tolerated and associated with significant reductions in clinical, HCRU and economic burden in post-acute care pediatric patients



# RESULTS

### GI INTOLERANCE SYMPTOMS (TABLE 2)

- Pre-index, 306 (65%) of children experienced GI intolerance symptoms, including constipation (36%), nausea and vomiting (36%), diarrhea (16%), and abdominal pain (14%).
- Use of CBTF was associated with a significant decrease in GI intolerance symptoms a 71% decrease in number of patients at 28 days post-discharge.
- Significantly fewer children experienced overall and individual GI intolerance symptoms at 28 days post-index while receiving the CBTF formula than pre-index (p<0.001).
- The reduction in GI intolerance symptoms was maintained at 84 days and 168 days post-index (p<0.001).

### HCRU BY VISIT TYPES

- While all patients required outpatient visits post-discharge, significantly fewer patients required emergency department visits, inpatient visits, urgent care and other services (such as assisted living, intermediate care, and care at other facilities) at all time points post-index compared with pre-index (p<0.05) (Figure 1).
- Mean emergency department (p<0.001), inpatient (p=0.014), and outpatient (p<0.001), visits per patient were significantly lower at 168 days post-index compared with pre-index (Figure 2).

### COST OF CARE BASED ON VISIT TYPES


• Reductions in HCRU at 168 days post-index resulted in significantly lower unadjusted mean total costs per patient for emergency department (p<0.001), inpatient (p=0.042), and outpatient (p<0.001) visits compared with pre-index (Figure 3).

Table 2: Patients experiencing GI intolerance symptoms, pre-index and post-index (N=469)

	Pre-index	28 days post-index		84 days post-index		168 days post-index	
	N (%)	N (%)	p <sup>†</sup>	N (%)	p <sup>†</sup>	N (%)	p <sup>†</sup>
Experience of GI Intolerance Symptoms	306 (65)	90 (19)	<0.001	118 (25)	<0.001	132 (28)	<0.001
Intolerance Symptoms							
Constipation	167 (36)	53 (11)	<0.001	68 (14)	<0.001	82 (17)	<0.001
Nausea & vomiting	168 (36)	36 (8)	<0.001	47 (10)	<0.001	56 (12)	<0.001
Abdominal pain	68 (14)	7 (1)	<0.001	9 (2)	<0.001	16 (3)	<0.001
Diarrhea	75 (16)	8 (2)	<0.001	13 (3)	<0.001	19 (4)	<0.001
Flatulence	54 (12)	7 (1)	<0.001	9 (2)	<0.001	12 (3)	<0.001
Gagging & retching	46 (10)	7 (1)	<0.001	12 (3)	<0.001	15 (3)	<0.001
Abdominal distension	44 (9)	5 (1)	<0.001	8 (2)	<0.001	11 (2)	<0.001


† Chi-square test (pre-index vs post-index); alpha=0.05 level of significance

Figure 2: Healthcare Resource Utilization in Post-Acute Care Patients Receiving CBTF Formulas



<sup>†</sup> t-test (pre-index vs post-index); alpha=0.05 level of significance; CBTF, commercial blenderized tube feeding

Figure 3: Cost Comparisons in Post-Acute Care Patients Receiving CBTF Formulas



†t-test (pre-index vs post-index); alpha=0.05 level of significance; CBTF, commercial blenderized tube feeding

## CONCLUSION

- A CBTF formula prescribed for children in the post-acute care setting was well tolerated and associated with significant reductions in GI intolerance symptoms.
- HCRU and associated costs were significantly lower post-index compared with pre-index, suggesting that CBTF formulas may have a potential role in improving clinical and health economic outcomes among children in post-acute care.

#### References

Gramlich L, et al. Nutrients. 2018;10(8).
Carvalho-Salemi J, et al. J Acad Nutr Diet. 2018;118(1):40-51 e47.
Hendricks KM, et al. Arch Pediatr Adolesc Med. 1995;149(10):1118-1122.
Toole BJ, et al. Congenit Heart Dis. 2014;9(1):15-25.
Boullata JI, et al. JPEN J Parenter Enteral Nutr. 2017;41(1):15-103.
Mundi MS, et al. Nutr Clin Prac. 2017;32(6):799-805.
Mundi MS, et al. Nutr Clin Prac. 2020;35(3):487-494.
DRG. Decision Resources Group (DRG) Real World Evidence US Data Repository.



Presented at ASPEN Nutrition Science & Practice Conference, March 26-29, 2022, Seattle, Washington.

Sponsored by Nestlé Health Science. Unless otherwise noted, all trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland.